Ocular allergy guidelines: A practical treatment algorithm

Drugs

Volumn 62, Issue 11, 2002, Pages 1611-1634

  Bielory, Leonard ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTAZOLINE; ANTIHISTAMINIC AGENT; AZELASTINE; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DECONGESTIVE AGENT; DENBUFYLLINE; DEXAMETHASONE; EMEDASTINE; KETOROLAC; KETOTIFEN; LEVOCABASTINE; LODOXAMIDE; NAPHAZOLINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; OXATOMIDE; PEMIROLAST; PEPLEOMYCIN; PHENIRAMINE; PHENYLEPHRINE; PICUMAST; SALBUTAMOL; SALMETEROL; TETRYZOLINE; THEOPHYLLINE; TRANILAST; UNINDEXED DRUG;

ALGORITHM; ALLERGIC CONJUNCTIVITIS; CLINICAL TRIAL; DRUG EFFECT; DRUG FORMULATION; EYE DISEASE; HUMAN; IMMUNOTHERAPY; KERATOCONJUNCTIVITIS; MULTICENTER STUDY; OCULAR ALLERGY; PRACTICE GUIDELINE; REVIEW; TH2 CELL; VERNAL CONJUNCTIVITIS;

EID: 0036329171     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200262110-00004     Document Type: Review

References (219)

1. Allergic and immunologic disorders of the eye. Part I: Immunology of the eye
2. Allergic and immunologic disorders of the eye. Part II: Ocular allergy
3. Update on ocular allergy treatment
4. Impact on quality of life during an allergen challenge research trial
5. Effects of Vasocon-A in the allergen challenge model of acute allergic conjunctivitis
6. Tolerance and absence of rebound vasodilation following topical ocular decongestant usage
7. Conjunctivitis medicamentosa
8. Comparison of topical nedocromil sodium and oral terfenadine for the treatment of seasonal allergic conjunctivitis
9. An evaluation of onset and duration of action of patanol (olopatadine hydrochloride ophthalmic solution 0.1%) compared to Claritin (loratadine 10 mg) tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model
10. The added benefit of local patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model
11. H2-receptors in the human ocular surface
12. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis
13. Levocabastine: Pharmacological profile of a highly effective inhibitor of allergic reactions
14. Absence of central effects with levocabastine eye drops
15. Effect of a new selective H1 receptor antagonist (levocabastine) in a nasal and conjunctival provocation test
16. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis
17. Pharmacodynamics of Amlexanox (AA-673) in normal and anaphylactic rat conjunctiva and its effect on histamine concentration
18. Inhibitory effect of levocabastine on experimental allergic conjunctivitis in guinea pigs
19. Effects of certain antiallergic drugs on experimental conjunctivitis in guinea pigs
20. Topical ocular levocabastine reduces ICAM-1 expression on epithelial cells both in vivo and in vitro
21. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms
22. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model
23. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: A multicenter comparison in patients with seasonal allergic conjunctivitis
24. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis
25. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis
26. A comparison of topical levocabastine and sodium cromoglycate in the treatment of pollen-provoked allergic conjunctivitis
27. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis
28. Levocabastine eye drops in the treatment of vernal conjunctivitis
29. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens
30. Safety and efficacy of topical levocabastine compared with oral terfenadine
31. Emedastine: A potent, high affinity histamine H1-receptor-selective antagonist for ocular use: Receptor binding and second messenger studies
32. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: Reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis
33. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model
34. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis
35. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis
36. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis
37. Experimental allergic conjunctivitis in guinea pigs induced by Japanese cedar pollen
38. Human conjunctival epithelial cells express histamine-1 receptors coupled to phosphoinositide turnover and intracellular calcium mobilization: Role in ocular allergic and inflammatory diseases
39. Histamine-stimulated cytokine secretion from human conjunctival epithelial cells: Inhibition by the histamine H1 antagonist emedastine
40. Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs
41. A current appreciation of sites for pharmacological intervention in allergic conjunctivitis: Effects of new topical ocular drugs
42. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells
43. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases
44. Olopatadine (AL-4943A): Ligand binding and functional studies on a novel, long acting H1-selective histamine antagonist and anti-allergic agent for use in allergic conjunctivitis
45. The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent
46. Olopatadine inhibits TNFalpha release from human conjunctival mast cells
47. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists
48. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model
49. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity
50. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate
51. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) using the provocative antigen challenge model
52. Inhibition of chemical mediator release from human leukocytes by a new antiasthma drug, HC 20-511 (ketotifen)
53. Inhibition of chemical mediator release from human leukocytes and lung in vitro by a novel antiallergic agent, KB-2413
54. Ketotifen. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders
55. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%
56. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model
57. Eye itching in ophthalmology and its treatment
58. A quantitative tear fluids determination of therapeutic efficacy for allergic conjunctivitis
59. Lens safety study with Picumast dihydrochloride: A double masked study using the Scheimpflug method
60. Eosinophil cationic protein and prophylactic treatment in pollinosis in natural allergen provocation
61. Protective effect of ketotifen, investigations in allergic children with bronchial asthma (author's transl)
62. Azelastine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
63. Intranasal azelastine: A review of its efficacy in the management of allergic rhinitis
64. The effect of azelastine on the early allergic response
65. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs
66. The effect of azelastine on neutrophil and eosinophil generation of superoxide
67. Modulation of in vitro anaphylaxis of guinea-pig isolated tracheal segments by azelastine, inhibitors of arachidonic acid metabolism and selected antiallergic drugs
68. Inhibition of leukotriene (SRS-A)-mediated acute lung anaphylaxis by azelastine in guinea pigs
69. Inhibition of allergic and nonallergic leukotriene C4 formation and histamine secretion by azelastine: Implication for its mechanism of action
70. Inhibition of 5-HETE, LTB4, and LTC4 formation by azelastine in rat mixed peritoneal cells
71. Azelastine: A novel in vivo inhibitor of leukotriene biosynthesis: A possible mechanism of action: A mini review
72. Suppression of TNF-alpha secretion by azelastine in a rat mast (RBL-2H3) cell line: Evidence for differential regulation of TNF-alpha release, transcription, and degranulation
73. Calcium signaling and protein kinase C for TNF-alpha secretion in a rat mast cell line
74. The effects of anti-asthma drugs on mediator release from cultured human mast cells
75. Allergic subjects express intercellular adhesion molecule - 1 (ICAM- 1 or CD54) on epithelial cells of conjunctiva after allergen challenge
76. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model
77. Azelastine eye drops reduce conjunctival hyperresponsiveness to hyperosmolar glucose challenge in children with asymptomatic mite conjunctivitis
78. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity
79. Effect of topical nasal pharmaceuticals on sodium and chloride transport by human airway epithelia
80. Modulation of eosinophilic chemotaxis with azelastine and budesonide in allergic patients
81. Effects of some anti-asthma drugs on human eosinophil superoxide anions release and degranulation
82. Inhibitory effect of azelastine hydrochloride on synthesis and release of platelet activating factor from human alveolar macrophages
83. Azelastine hydrochloride (Azeptin) inhibits peplomycin (PLM)-induced pulmonary fibrosis by contradicting the up-regulation of signal transduction
84. Effect of azelastine on PGE2 production in fibroblasts in normal skin. The possibility of inhibition of inducible cyclooxygenase by azelastine
85. Azelastine suppresses the release of arachidonic acid metabolites from cultured human umbilical vein endothelial cells
86. Suppression by azelastine hydrochloride of NF-κ B activation involved in generation of cytokines and nitric oxide
87. 5-Lipoxygenase inhibitory and antihistamine activities of linetastine
88. Inhibition of collagen expression by azelastine hydrochloride in cultured skin fibroblasts from normal individuals and scleroderma patients
89. Inhibition of cytokine production from human peripheral blood leukocytes by antiallergic agents in vitro
90. Effects of anti-allergy drugs on fMet-Leu-Phe-stimulated superoxide generation in human neutrophils
91. Effects of the antiallergic drug azelastine hydrochloride on proliferative responses of lymphocytes to food antigens in patients with food-sensitive atopic dermatitis
92. Suppression of respiratory burst of polymorphonuclear leukocytes by azelastine hydrochloride (Azeptin)
93. Inhibitory effect of azelastine, a potent antiallergic agent, on release of tumor necrosis factor-alpha from activated human peripheral blood mononuclear cells and U937 cells
94. Stimulated elastase release from human leukocytes: Influence of anti-asthmatic, anti-inflammatory and calcium antagonist drugs in vitro
95. Azelastine potentiates the prostaglandin-induced increase of cyclic AMP content in human platelets and in guinea-pig alveolar macrophages
96. Effects of azelastine on neutrophil chemotaxis, phagocytosis and oxygen radical generation
97. Suppressive effect of azelastine on the induction of Df antigen specific IL-2 responsiveness in lymphocytes from patients with bronchial asthma
98. Azelastine inhibits stimulated histamine release from human lung tissue in vitro but does not alter cyclic nucleotide content
99. Development of a system for monitoring the production of leukotriene B4, C4, D4 and E4 in whole blood of pediatric asthmatic patients
100. Nedocromil sodium: A review of the evidence for a dual mechanism of action
101. Nedocromil sodium: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease
102. Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers
103. Nedocromil sodium prevents in vivo generation of the eosinophilotactic substance induced by PAF but fails to antagonize its effects
104. Effects of nedocromil sodium on antigen-induced conjunctivitis in guinea pigs
105. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen
106. Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium
107. Double-blind group comparative study of 2% nedocromil sodium eye drops with placebo eye drops in the treatment of seasonal allergic conjunctivitis
108. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis
109. The effect of sodium cromoglycate eyedrops compared to the effect of terfenadine on acute symptoms of seasonal allergic conjunctivitis
110. A double-blind group comparative study of ophthalmic sodium cromoglycate, 2% four times daily and 4% twice daily, in the treatment of seasonal allergic conjunctivitis
111. Evaluation of nedocromil sodium 2% ophthalmic solution for the treatment of seasonal allergic conjunctivitis
112. Efficacy and safety of nedocromil sodium 2% ophthalmic solution b.i.d. in the treatment of ragweed seasonal altergic conjunctivitis
113. Effectiveness of nedocromil sodium 2% eyedrops on clinical symptoms and tear fluid cytology of patients with vernal conjunctivitis
114. Treating severe eye allergy
115. Nedocromil sodium eye drops are more effective than sodium cromoglycate eye drops for the long-term management of vernal keratoconjunctivitis
116. Nedocromil sodium treats symptoms of perennial allergic conjunctivitis not fully controlled by sodium cromoglycate
117. Clinical experience with Tilavist: An overview of efficacy and safety
118. Efficacy and acceptabitity of nedocromil sodium 2% and olopatadine hydrochloride 0.1% in perennial allergic conjunctivitis
119. Efficacy of nedocromil 2% versus fluorometholone 0.1%: A randomised, double masked trial comparing the effects on severe vernal keratoconjunctivitis
120. Nedocromil sodium in contact-lens-associated papillary conjunctivitis
121. Quality of life in multi-centre trials
122. Clinical trials of disodium cromogtycate in vernal conjunctivitis
123. Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cell in vitro
124. Disodium cromoglycate inhibits S mu - >S epsilon deletional switch recombination and IgE synthesis in human B cells
125. Ocular sodium cromoglycate: An overview of its therapeutic efficacy in allergic eye disease
126. Development of new antiallergic drugs (cromolyn sodium, lodoxamide tromethamine): What is the rote of cholinergic stimulation in the biphasic dose response?
127. Effects of lodoxamide, disodium cromoglycate and fluorometholone on tear leukotriene levels in vernal keratoconjunctivitis
128. Effect of lodoxamide on tear leukotriene levels in giant papillary conjunctivitis associated with ocular prosthesis
129. Tear histamine and histaminase during the early (EPR) and late (LPR) phases of the allergic reaction and the effects of lodoxamide
130. Efficacy of lodoxamide eye drops on mast cells and eosinophils after allergen challenge in allergic conjunctivitis
131. Efficacy of lodoxamide 0.1% ophthalmic solution in resolving corneal epitheliopathy associated with vernal keratoconjunctivitis
132. Suppression of conjunctival provocation by 0.1% pemirolast potassium ophthalmic solution in VKC
133. Interactive effects of peptidoleukotrienes and histamine on microvascular permeability and their involvement in experimental cutaneous and conjunctival immediate hypersensitivity
134. The pruritogenic and inflammatory effects of prostanoids in the conjunctiva
135. Characterization of receptor subtypes involved in prostanoid-induced conjunctival pruritus and their role in mediating allergic conjunctival itching
136. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis
137. Topical ketorolac 0.5% solution for the treatment of vernal keratoconjunctivitis
138. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis
139. Double-masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis
140. Allergic conjunctivitis and uveitis models: Reappraisal with some marketed drugs
141. Contact lens induced conjunctivitis: A model of human ocular inflammation
142. Asthma caused by topical application of ketorolac
143. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis
144. A randomized, double-masked, placebo-controlled parallel study of 0.2% loteprednol etabonate in patients with seasonal allergic conjunctivitis
145. Loteprednol etabonate: A review of ophthalmic clinical studies
146. A randomized, double-masked, placebo-controlled parallel study of loteprednol etabonate 0.2% in patients with seasonal allergic conjunctivitis
147. The conjunctival provocation test model of ocular allergy: Utility for assessment of an ocular corticosteroid, loteprednol etabonate
148. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis
149. Loteprednol etabonate: Comparison with other steroids in two models of intraocular inflammation
150. Pharmacokinetic characterization and tissue distribution of the new glucocorticoid soft drug loteprednol etabonate in rats and dogs
151. Prophylactic inoculation against hay fever
152. Uveitogenic potential of lymphocytes sensitized to interphotoreceptor retinoid-binding protein
153. The immunology of the eye and its systemic interactions
154. Immunomodulation of experimental autoimmune uveoretinitis: A model of tolerance induction with retinal antigens
155. Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: Suppression of experimental autoimmune uveoretinitis is retinal antigen specific
156. Basic and clinical immunology in uveitis
157. Histopathologic analysis of experimental autoimmune uveitis attenuated by intracameral injection of S-antigen
158. Immunopharmacological studies of qingkaining, a Chinese blended medicine: Effects on experimental autoimmune uveoretinitis in the rat
159. Immunotherapy in ocular diseases
160. Inhibition of experimental autoimmune uveoretinitis by oral administration of S-antigen and synthetic peptides
161. Lymphocyte subsets in conjunctival mucosa-associated-lymphoid-tissue after exposure to retinal-S-antigen
162. Uveitis induced in primates by IRBP: Humoral and cellular immune responses
163. Suppression of experimental autoimmune uveitis in mice by induction of anterior chamberassociated immune deviation with interphotoreceptor retinoid-binding protein
164. Effects of experimental ocular inflammation on ocular immune privilege
165. A double-blind study of the effectiveness and specificity injection therapy in ragweed hay fever
166. Comparison of the efficacy and side effects of aqueous steroid nasal spray (budesonide) and allergen-injection therapy (Pollinex-R) in the treatment of seasonal allergic rhinoconjunctivitis
167. Local specific immunotherapy in allergic conjunctivitis
168. Nasal immunotherapy in weed-induced allergic rhinitis
169. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens
170. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation: I. Clinical results
171. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study
172. A double-blind, randomized study investigating the efficacy and specificity of immunotherapy with Artemisia vulgaris or Phleum pratense/betula verrucosa
173. Efficacy of immunotherapy to ragweed antigen tested by controlled antigen exposure
174. Clinical effects of immunotherapy on Japanese cedar pollinosis in the season of cedar and cypress pollination
175. Allergen-specific immunotherapy in birch- and grass-pollen-allergic rhinitis: I. Efficacy estimated by a model reducing the bias of annual differences in pollen counts
176. Induction of oral tolerance to experimental allergic conjunctivitis in rats
177. Local ocular immunotherapy for experimental allergic conjunctivitis
178. Prevention of acute allergic conjunctivitis and late-phase inflammation with immunostimulatory DNA sequences
179. Oral immunotherapy in birch pollen hay fever
180. Sublingual immunotherapy with a standardised grass pollen extract; a double-blind placebo-controlled study
181. Sublingual-swallow immunotherapy (SLIT) with a standardized five-grass-pollen extract (drops and sublingual tablets) versus placebo in seasonal rhinitis
182. N-acetyl-aspartylglutamic acid eye drops in allergic-type conjunctivitis. Double-blind comparative clinical study
183. Seasonal and chronic allergic conjunctivitis in adults with children. Multicenter evaluation of the collyrium N-acetylaspartyl-glutamic acid (NAAGA) in ophthalmologic and allergy practices
184. Treatment of common ocular allergic disorders; a comparison of lodoxamide and NAAGA
185. Efficacy of lodoxamide 0.1% versus N-acetyl aspartyl glutamic acid 6% ophthalmic solutions in patients with vernal keratoconjunctivitis
186. N-acetyl-aspartyl glutamic acid (NAAGA) topical eyedrops in the treatment of giant papillary conjunctivitis (GPC)
187. Effects of lodoxamide (LOD), disodium cromoglycate (DSCG) and N-acetyl-aspartyl-glutamate sodium salt (NAAGA) on ocular active anaphylaxis
188. Treatment of Ligneous conjunctivitis with membrane excision and prophylactic topical heparin and alpha-chymotrypsin
189. Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops
190. Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis
191. The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis
192. Anti-inflammatory effect of cyclosporin A on human skin mast cells
193. Dexamethasone or cyclosporin A suppress mast cell-leukocyte cytokine cascades. Multiple mechanisms of inhibition of IgE- and mast cell-dependent cutaneous inflammation in the mouse
194. Dexamethasone and cyclosporin A suppress mast cell-leukocyte cytokine cascades by multiple mechanisms
195. Topical cyclosporine inhibits mast cell-mediated conjunctivitis
196. Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjogren's syndrome
197. Systemic cyclosporine A in severe atopic keratoconjunctivitis
198. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: The effect of topical Cyclosporin A therapy
199. The pathology of dry eye: The interaction between the ocular surface and lacrimal glands
200. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes
201. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease: CsA Phase 3 Study Group
202. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: A dose-ranging, randomized trial: The Cyclosporin A Phase 2 Study Group
203. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion
204. The mechanism of action of FK-506 and cyclosporin A
205. Molecular mechanisms of the immunosuppressive action of cyclosporin A
206. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription
207. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms
208. Cyclosporine, FK506, mycophenolate mofetil, and prednisolone differentially modulate cytokine gene expression in human airway-derived epithelial cells
209. The impact of immunosuppressive drugs on the analysis of T cell activation
210. Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye
211. Topical application of ciclosporin ophthalmic solution containing alpha-cyclodextrin in experimental uveitis
212. Influence of vehicle and anterior chamber protein concentration on cyclosporine penetration through the isolated rabbit cornea
213. Prevention of allergic eye disease by treatment with IL- 1 receptor antagonist
214. Soluble P-selectin glycoprotein ligand 1 inhibits ocular inflammation in a murine model of allergy
215. Blocking ICAM-1 (CD54) and LFA-1 (CD 11a) inhibits experimental allergic conjunctivitis
216. Peptide inhibition of the Prausnitz-Kustner reaction
217. Safety and efficacy of human IgE pentapeptide
218. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
219. Human conjunctival mast cells: Expression of Fc epsilonRI, c-kit, ICAM-1, and IgE